Nasdaq gnlx.

Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...Nov 14, 2023 · WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ... Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a …20. 11. 2023 ... (NASDAQ:KRRO) fell 8.9% to $35.51. Genelux Corporation (NASDAQ:GNLX) fell 8.7% to $10.83. Chegg, Inc. (NYSE:CHGG) shares declined 8.2% to ...CIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ...

Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%. Key Insights Significant control over Genelux by retail investors …Genelux Corp. GNLX, +12.02% has set terms for its initial public offering, in which the California-based biotechnology company focused on treating difficult-to-treat tumors could be valued at up ...Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX...

Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …

1. 6. 2023 ... The stock jumped after the company released, late last week, positive phase 2 data on the its lead therapy. Expand. NASDAQ: GNLX. Genelux.The latest price target for . Genelux (NASDAQ: GNLX) was reported by Maxim Group on September 12, 2023.The analyst firm set a price target for $40.00 expecting GNLX to rise to within 12 months (a ...About This Event Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for ...GNLX Genelux Corporation Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

GNLX GNLX Genelux Corp NASDAQ 20.01 -0.03 -0.15% After Hours: 20.01 0 0.00% 16:01 10/19 EDT OPEN 20.00 PREV CLOSE 20.04 HIGH 20.40 LOW 20.00 VOLUME 101.28K …

Genelux (NASDAQ:GNLX – Get Free Report) had its price target reduced by equities researchers at Benchmark from $38.00 to $30.00 in a research note issued on Friday, Benzinga reports. The firm presently has a “speculative buy” rating on the stock. Benchmark’s price target points to a potential upside of 170.27% from the company’s …Web

On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, representing a significant increase from its one-year low of $5.35 and a modest uptick from its impressive one-year high of $39.27. The stock’s 50-day simple moving average is currently resting at $26.83, indicating a positive trend that is grabbing the attention of expert market analysts.GNLX Genelux Corporation Form 8-K - Current report. 0001231457 false 0001231457 2023-10-10 2023-10-10 iso4217:USD xbrli:shares ... Monitor; Level 2; Movers; Portfolio; Markets; Forums; Menu ...Genelux Corporation (NASDAQ:GNLX) gained 12.9% to $30.82. Franchise Group, Inc. (NASDAQ:FRG) jumped 11.8% to $25.44. Franchise Group revealed the receipt of an unsolicited non-binding proposal to ...Find the latest historical data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Genelux Corporation (NASDAQ:GNLX) gained 10.5% to $5.02. Latham Group, Inc. (NASDAQ:SWIM) gained 10.2% to $3.7050 following Q4 results. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rose 9.6% to $7.75 ...

Given GNLX’s positive Phase 2 trial results to-date, my outlook on IPO is a Buy for patient, risk-tolerant life science investors with a long-term hold time frame. ... (NASDAQ:GNLX) was founded ...WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...A high-level overview of Genelux Corporation (GNLX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Genelux has filed to go public with an IPO on the NASDAQ. 1 year ago - SEC. Get a real-time Genelux Corporation (GNLX) stock price quote with breaking news, …The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 32.13 / share. This is an increase of 80.00% from the prior estimate of 17.85 dated June 1, 2023.

WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WebGenelux press release (NASDAQ:GNLX): Q3 GAAP EPS of -$0.20 misses by $0.02. $29.9 million in cash and equivalents. Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage ...

Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a …20. 11. 2023 ...What happenedShares of Genelux (NASDAQ: GNLX) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech ...In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebView real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Oct 13, 2023 · Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of. Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 18:25:17. $5.8.

The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 32.13 / share. This is an increase of 80.00% from the prior estimate of 17.85 dated June 1, 2023.

NVIDIA Corporation Common Stock. $435.70 -0.93 -0.21%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...

Genelux Corporation's (NASDAQ:GNLX) value has fallen 16% in the last week, but insiders who sold US$11m worth of stock over the last year have had less success. Insiders might have been better off holding onto their shares, given that the average selling price of US$23.49 is still below the current share price.Genelux Corp (NASDAQ:GNLX) Benchmark initiated coverage on Genelux with a Speculative Buy rating and announced a price target of $10. The company’s stock has a 52-week high of $13.28 .As of this writing, Genelux Corp (NASDAQ:GNLX) shares are trading at above $22.30 with a 52-week range of $5.35 to $39.27, giving the company a market capitalization of more than $527 million. 2 ...Sep 8, 2023 · In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings. In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.Genelux (NASDAQ: GNLX) is owned by 15.88% institutional shareholders, 5.64% Genelux insiders, and 78.48% retail investors. Aladar Szalay is the largest individual Genelux shareholder, owning 555,000.00 shares representing 2.08% of the company. Aladar Szalay's Genelux shares are currently valued at $6.21M.So far, 2023 has been a great year for Genelux Corporation (NASDAQ:GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that’s primarily ...WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ...Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions.

Genelux Corp. GNLX (U.S.: Nasdaq) Overview Profile Financials Income Statement Balance Sheet Cash Flow Research & Ratings Historical Prices Options Advanced Charting News Genelux Corp. No...Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for each option strike price and expiration month. call and put options ...NASDAQ:GNLX. Exchange/Ticker 2: N/A. Latest Market Cap: $311,897,408. BioCentury | Aug 28, 2023. Management Tracks. Kurt Graves takes top spot at i2o. Plus ...Instagram:https://instagram. jim cramer stocksamerican builders insurancewhat is best day trading platformvision plans in pa On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, representing a significant increase from its one-year low of $5.35 and a modest uptick from its impressive one-year high of $39.27. The stock’s 50-day simple moving average is currently resting at $26.83, indicating a positive trend that is grabbing the attention of expert market analysts. best mortgage lenders for rental propertypdt td ameritrade WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...Jan 27, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history. software for investment portfolio management The average price predicted for Genelux Corp (GNLX) by analysts is $36.00, which is $22.03 above the current market price. The public float for GNLX is 18.34M, and at present, short sellers hold a 4.76% of that float. On November 07, 2023, the average trading volume of GNLX was 223.78K shares. Top 5 AI Stocks to Buy for 2023.add_box. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...Web